BioCentury | Oct 27, 2020
Distillery Therapeutics

FAP inhibition for the treatment of osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis The endogenous bone growth factor CLEC11A and other inhibitors of FAP could treat osteoporosis. In cultures of mouse primary bone marrow cells, a tool compound FAP inhibitor reduced osteoclast differentiation. In...
BioCentury | Oct 7, 2020
Politics, Policy & Law

FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress

In a move that raises concerns about the accuracy of tests, as well as liability protections for laboratories, FDA announced Wednesday that it will no longer review emergency use authorization requests for laboratory-developed tests to...
BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

The move to digital launch models that emerged during the pandemic is likely to permanently change the way biopharma companies approach new drug sales, with knock-on effects for partnering trends and pipeline...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis; herpes simplex virus (HSV) Inhibiting CXCL1 or its receptor, CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1 encephalitis, systemic knockout of CXCR2 lowered disease scores, improved survival and reduced...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Activating potassium channel KCNJ3 to treat epilepsy

DISEASE CATEGORY: Neurology INDICATION: Epilepsy A thiophenylurea-based activator of the potassium channel KCNJ3 could treat epilepsy. In a mouse model of chemically induced epilepsy, the KCNJ3 activator reduced seizure severity and the duration of tonic...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Democrats, Republicans could find common ground on drug pricing recommendations from Biden-Sanders task force

Recommendations from a task force assembled by Joe Biden and Sen. Bernie Sanders (I-Vt.) include several healthcare policies favored by Democrats, like Medicare drug price negotiation, but stop short of Medicare for All. The bulk...
BioCentury | Jul 6, 2020
Politics, Policy & Law

Trump to sign drug pricing order, chief of staff says

President Donald Trump will sign executive orders this week on drug pricing, bringing manufacturing back to the U.S., and immigration, White House Chief of Staff Mark Meadows said Monday in a television interview on Fox...
BioCentury | Jun 19, 2020
Politics, Policy & Law

House lawmakers call for transparency, independent review for COVID-19 vaccine program

A trio of Democrats on the House Oversight Committee are asking FDA for more information on how the agency plans to evaluate and deploy COVID-19 vaccines, in an effort to ensure the process is transparent,...
Items per page:
1 - 10 of 1461